Approval · Notice of Compliance 37187 · 2026
VANFLYTA: Notice of Compliance 37187
Issued March 25, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37187
- Date
- March 25, 2026
- Company
- Daiichi Sankyo Pharma Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VANFLYTA | Not yet assigned | — |
Medicinal ingredients
- QUIZARTINIB HYDROCHLORIDE 17.7 MG per TAB
- QUIZARTINIB HYDROCHLORIDE 26.5 MG per TAB